N/A N=96 A Walking Intervention Through Text Messaging
Physical Activity · Behavior · Overweight
Primary: Change in Fitbit-measured Steps/Day and Moderate-to-vigorous Physical Activity Between Study Arms. — 9695; 9836; 10562; 8969 steps
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=76 Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial
Gastroesophageal Reflux Disease
Primary: CLINICAL OUTCOME OF FEEDING SUCCESS — 33; 44 percentage of participants — p=0.28
N/A N=692 POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE
Carotid Artery Disease
Primary: Number of Participants With Procedural Success — 630; 690 Participants
N/A N=117 Alzheimer's Prevention Through Exercise
Alzheimer's Disease
Primary: Amyloid Burden — 1.20; 1.22; 1.21; 1.22 Standard Uptake Value Ratio (SUVR)
N/A N=56 Enhanced Recovery After Spine Surgery
Enhanced Recovery After Surgery · Spine Surgery
Primary: Patient Score on QoR40 Inventory. — 179.4; 170.3 scores on a scale
N/A N=32 Therapeutic Effects of Constraint-Induced Movement Therapy on Young Children With Cerebral Palsy
Cerebral Palsy Spastic Hemiplegic
Primary: Change From Baseline Pediatric Motor Activity Log (PMAL) Score at Post Test — 0.83; 0.00; 0.50; -0.05 score on a scale
Phase 2 N=255 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
Multiple Sclerosis, Primary Progressive · Multiple Sclerosis, Secondary Progressive
Primary: Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF). — -0.00168; -0.00392 ratio — p=0.04
Phase 3 N=939 A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Macular Degeneration
Primary: Percentage of Participants With Stable Vision at Week 52 — 91.7; 91.2; 95.5 percentage of participants
Phase 3 N=298 Study of Urate Elevation in Parkinson's Disease, Phase 3
Parkinson's Disease
Primary: Rate of Clinical Decline — 11.116; 9.860 score per year — p=0.183
N/A N=23 Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA
Obstructive Sleep Apnea · Chronic Obstructive Pulmonary Disease · Overlap Syndrome
Primary: Right Ventricular Remodeling Index — 0.3747; 0.2817 ratio
N/A N=48 Adherence for Exercise Rehabilitation in Older People Trial
Geriatric · Exercise Adherence
Primary: Self-reported Adherence — 6.77; 7.35; 6.60; 7.10 score on a scale
Phase 4 N=1,027 A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants Achieving 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI 100) — 41.3; 24.9 percentage of participants — p=<0.001
Phase 3 N=202 Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
Hyperphosphatemia
Primary: Change From Baseline in Serum Phosphorus at Week 8 — 2.090; 2.095; 0.010; -0.200 mmol/L — p=<0.0001
N/A N=5 Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension
Intracranial Hypotension
Primary: Intracranial Pressure Measurements Estimated by the MRICP Technique. — 6.5 cm H20
Phase 1 N=31 Biological Signatures, Probiotic Among Those With mTBI and PTSD
Mild Traumatic Brain Injury · Post Traumatic Stress Disorder
Primary: C-Reactive Protein Change — 0.113; -0.625 mg/L — p=.056